Boston Scientific was the worst performer in the S&P 500 Wednesday after the medical-device maker beat earnings expectations but offered a disappointing outlook for the current quarter.

A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024 at Alumni Stadium in ...

Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was ...

Despite growing sales and adjusted EPS by 16% and 14% in Q4 -- easily beating Wall Street’s estimates -- Boston Scientific stock dropped 18% on Wednesday due to “weak” guidance. More specifically, the ...

Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market. Ultimately, Boston Scientific's earnings ...

Boston Scientific (NYSE: BSX) + shares tumbled before hours today despite fourth-quarter results that topped the consensus forecast. Shares of BSX fell by more than 10% to $81.55 apiece in pre-market ...

Boston Scientific reported Q4 adjusted earnings of 80 cents per share, beating analyst estimates of 78 cents Net sales reached $5.29 billion with 12.7% organic growth, slightly above Wall Street ...